2013
DOI: 10.3109/15622975.2013.829585
|View full text |Cite
|
Sign up to set email alerts
|

Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?

Abstract: Objectives Preclinical and clinical research in neuropsychiatric disorders, particularly mood and substance use disorders, have historically focused on neurons; however, glial cells – astrocytes, microglia, and oligodendrocytes – also play key roles in these disorders. Methods Peer-reviewed PubMed/Medline articles published through December 2012 were identified using the following keyword combinations: glia, astrocytes, oligodendrocytes/glia, microglia, substance use, substance abuse, substance dependence, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
23
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(23 citation statements)
references
References 183 publications
0
23
0
Order By: Relevance
“…Further, reductions in expression of GFAP have been reported in both preclinical animal models of depression, as well as in human postmortem studies of psychiatric disease, most notably depression but also schizophrenia (for review, see (4042)). Indeed, considerable evidence from the human literature indicates that glial dysfunction and more specifically decreased astrocyte density and astrocyte-mediated glutamate uptake may reflect a cellular feature of the high degree of comorbidity observed between substance use disorders and depression (43). …”
Section: Discussionmentioning
confidence: 99%
“…Further, reductions in expression of GFAP have been reported in both preclinical animal models of depression, as well as in human postmortem studies of psychiatric disease, most notably depression but also schizophrenia (for review, see (4042)). Indeed, considerable evidence from the human literature indicates that glial dysfunction and more specifically decreased astrocyte density and astrocyte-mediated glutamate uptake may reflect a cellular feature of the high degree of comorbidity observed between substance use disorders and depression (43). …”
Section: Discussionmentioning
confidence: 99%
“…Thus, 1 H-MRS measurement of glutamine may provide an index of astrocytic functioning relating to this particular cycle; the ratio of glutamine-to-glutamate may be particularly salient. Notably, alterations in glutamine (2) and astrocyte functionality (36) have been associated with a number of psychiatric conditions.…”
Section: Discussionmentioning
confidence: 99%
“…It has been suggested that the interaction between depression and SUD could lead to glial dysfunction and a consequent alteration in glutamatergic neurotransmission [57, 58], so the pharmacological modulation of this circuit may play a key role in the treatment of SUD in comorbidity with other mental disorders. Ketamine, a glutamate-modulating agent, has been shown to reduce suicide in high-risk populations [58-60], so the inclusion of this medication in the treatment of subjects with SUD with suicidal tendencies is an option that would be worth exploring.…”
Section: Discussionmentioning
confidence: 99%